You cannot register anymore for this webinar

Obesity: Metabolic Activation of Fibroblasts and Related Disorders

Our next webinar will delve into the role of metabolic activation of fibroblasts, particularly focusing on obesity and obesity-related disorders such as liver, heart, and kidney diseases.

Join us for a live webinar where leading experts will discuss the critical role fibroblasts play in metabolic disorders. The presentations will highlight recent research findings and explore the therapeutic potential of modulating fibroblast activity to improve patient outcomes.

The speakers will take you on a journey through the latest research and developments in the field of fibroblast activation in metabolic disorders. They will discuss how modulating fibroblast activity can lead to significant improvements in patient outcomes, particularly in obesity-related conditions affecting the liver, heart, and kidneys.

Can’t wait until the webinar? Here’s a sneak peek of Professor Jörn Shattenberg’s talking points:
  • The mechanisms of metabolic activation and de-activation of fibroblasts in MAFLD.
  • The role of weight loss in modulating fibroblast activity.
  • How these changes can improve liver health and patient outcomes.

More information about our speakers:
Webinars - ECM Congress (ecm-congress.org)
Want to watch the replay? Click here!

Agenda


11:00 – 11:10 | Opening of the session

11:10 – 11:30 | Metabolic activation of ECM production of fibroblast and the relation to outcomes in heart, liver and kidney diseases – Professor Morten Karsdal

11:30 – 11:50 | Metabolic activation and de-activation of fibroblasts in MAFLD by weight loss. The weight-dependent angle – Professor Jörn M. Shattenberg

11:50 – 12:10 | Pharmacological modulation of fibroblast activation and the benefit for patients – Dr. Diana J. Leeming

12:10 – 12:30 | General discussion and questions
*All times EDT. Agenda is subject to change as per speaker availability.

Expected duration
90 minutes

Share this webinar